Use of Platelets and Other Transfusion Products in Patients with Malignancy
| Autor: | Mary E. Adams, Lowell L. Tilzer, David C. Bodensteiner, William L. Bayer |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
medicine.medical_specialty
Resuscitation Blood Component Transfusion Blood Donors Malignancy Hospitals University Sepsis Risk Factors Neoplasms Internal medicine medicine Humans Platelet Intensive care medicine Hematology business.industry Cancer Kansas medicine.disease Hematologic Diseases Surgery Platelet transfusion Fresh frozen plasma Cardiology and Cardiovascular Medicine business |
| Zdroj: | Seminars in Thrombosis and Hemostasis. 18:380-391 |
| ISSN: | 1098-9064 0094-6176 |
| Popis: | The need for blood components for oncology patients is small compared with the need for patients with hematologic malignancies. Appropriate use of blood components is necessary, not only medically, but also because of limited supply and availability. Agreement on when to use components is extremely important. In fact, at the time of this writing, the Transfusion Practices Committee of the AABB is conducting an extensive survey on the use of platelets in the oncology and hematology cancer patients (Questionnaire on Institutional Policy on Platelet Transfusion Practice for Hematology/Oncology Patients). The results will, it is hoped, provide a consensus on the proper times and counts that require prophylactic use of components for these patients. Since these patients use the vast majority of components (see Table 15), their proper use is imperative to maintaining an adequate platelet and frozen plasma supply. Transfusion support in cancer patients is vital for their survival. Platelets, in particular, are necessary to prevent serious bleeding. However, refractoriness to platelet transfusions can develop. It must be appreciated that refractoriness is not a general problem and need not require the expensiveness of a universal decision for handling all platelet transfusions in the same manner. Total refractoriness probably occurs in 15 to 20% of patients frequently transfused. In patients in whom frequent platelet transfusion is anticipated, that is, bone marrow transplantation, the development of platelet refractoriness may be reduced by using SDPC and administering them through leukocyte filters. Patients who become refractory to either random or SDPC can either be cross-matched for single-donor platelets that are compatible or can be given HLA-A,B matched platelets. Certainly, the success of platelet transfusion in leukemic patients cannot be denied, since only a small number of these patients now die because of bleeding due to platelet refractoriness. Most of the serious bleeding still seen is associated with sepsis. The risks from transfusion must always be considered. Fortunately, with increased monitoring of the blood supply, they have been reduced. As with any therapeutic regimen, these risks must be weighed against the benefit the patient may gain. Transfusion should always be used prudently. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|